May 24, 2024 07:15 AM EDTUpdated 08:02 AM R&DPharma AUTHORKatherine LewinNews [email protected] Novo Nordisk’s semaglutide cut the risk of major cardiovascular events and death from multiple causes in a Phase 3 study involving patients with type 2 diabetes and chronic kidney disease, building the company’s case for expanding the drug in a broad range of...
Tag: <span>death risk reduction</span>
Post
mRNA skin cancer therapy halves risk of death in clinical trial
By Michael Irving mRNA technology has proven promising against skin cancer in a new phase 2b clinical trial Depositphotos Moderna has announced the results of a Phase 2b trial investigating its mRNA treatment for skin cancer, and it continues a streak of promising news. When paired with an immunotherapy, the treatment significantly reduced the risks of...